BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20446856)

  • 1. Tiotropium therapy and mortality risk in COPD patients: the most severe, the most protected? Evaluation of Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180(10): 948-55.
    Sampablo I; Carone M; Antoniu SA
    Expert Opin Pharmacother; 2010 Jun; 11(8):1439-41. PubMed ID: 20446856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial.
    Tashkin DP
    Expert Rev Respir Med; 2010 Jun; 4(3):279-89. PubMed ID: 20524910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.
    Tashkin DP
    Am J Med; 2006 Oct; 119(10 Suppl 1):63-72. PubMed ID: 16996901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).
    Morice AH; Celli B; Kesten S; Lystig T; Tashkin D; Decramer M
    Respir Med; 2010 Nov; 104(11):1659-67. PubMed ID: 20724131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The verge and the abyss: tiotropium (Spiriva) in COPD].
    Segel MJ; Ben-Dov I
    Harefuah; 2011 Jan; 150(1):61-3, 66. PubMed ID: 21449160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety.
    Tashkin DP
    Curr Opin Pulm Med; 2010 Mar; 16(2):97-105. PubMed ID: 20019615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tiotropium (Spiriva) - a long-acting inhaled anticholinergic for the treatment of chronic obstructive pulmonary disease (COPD)].
    Beeh KM; Welte T; Buhl R
    Pneumologie; 2003 Sep; 57(9):519-25. PubMed ID: 13680472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tiotropium: a bronchodilator for chronic obstructive pulmonary disease.
    Somand H; Remington TL
    Ann Pharmacother; 2005 Sep; 39(9):1467-75. PubMed ID: 16030078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tiotropium, a long-acting bronchodilating agent for the treatment of COPD].
    Schuurbiers OC; Schermer TR; Dekhuijzen PN; van Weel C
    Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1227-32. PubMed ID: 16796173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of replacing oxitropium with tiotropium on pulmonary function in patients with COPD: a randomized study.
    Incorvaia C; Riario-Sforza GG; Pravettoni C; Dugnani N; Paterniti F; Pessina L; Fumagalli M
    Respir Med; 2007 Mar; 101(3):476-80. PubMed ID: 16919926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival with tiotropium compared to long-acting Beta-2-agonists in Chronic Obstructive Pulmonary Disease.
    Gershon AS; Wang L; To T; Luo J; Upshur RE
    COPD; 2008 Aug; 5(4):229-34. PubMed ID: 18671148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.
    Lee TA; Wilke C; Joo M; Stroupe KT; Krishnan JA; Schumock GT; Pickard AS
    Arch Intern Med; 2009 Aug; 169(15):1403-10. PubMed ID: 19667304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.
    Chen AM; Bollmeier SG; Finnegan PM
    Ann Pharmacother; 2008 Dec; 42(12):1832-42. PubMed ID: 18957624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
    Baker WL; Baker EL; Coleman CI
    Pharmacotherapy; 2009 Aug; 29(8):891-905. PubMed ID: 19637942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of tiotropium in Chinese patients with stable chronic obstructive pulmonary disease: a meta-analysis.
    Wu Q; Li G; Lei WI; Zhou X
    Respirology; 2009 Jul; 14(5):666-74. PubMed ID: 19402836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
    Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
    Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD.
    Eguchi Y; Tateishi Y; Umeda N; Yoshikawa T; Kamoi H; Kanazawa H; Kudoh S; Hirata K; Fujimoto S
    Osaka City Med J; 2007 Jun; 53(1):25-34. PubMed ID: 17867631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of tiotropium in the prevention of exacerbations of COPD.
    Anzueto A; Miravitlles M
    Ther Adv Respir Dis; 2009 Jun; 3(3):103-11. PubMed ID: 19617284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes.
    Yohannes AM; Willgoss TG; Vestbo J
    Respir Care; 2011 Apr; 56(4):477-87. PubMed ID: 21255503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TORCH and UPLIFT: what has been learned from the COPD "mega-trials"?
    Niewoehner DE
    COPD; 2009 Feb; 6(1):1-3. PubMed ID: 19229702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.